Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,600 | -13,037 | -6,536 | -27,299 | -21,466 |
| Depreciation Amortization | 179 | 125 | 67 | 239 | 171 |
| Other Working Capital | 7,353 | 4,997 | 3,591 | -2,864 | -1,146 |
| Other Operating Activity | 5,489 | 3,600 | 1,737 | 7,238 | 5,450 |
| Operating Cash Flow | $-8,579 | $-4,315 | $-1,141 | $-22,686 | $-16,991 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -2,500 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 775 | N/A | N/A | 729 | 729 |
| Financing Cash Flow | $-1,725 | $N/A | $N/A | $729 | $729 |
| Exchange Rate Effect | -36 | -13 | -9 | -700 | -1,143 |
| Beginning Cash Position | 52,153 | 52,153 | 52,153 | 74,810 | 74,810 |
| End Cash Position | 41,813 | 47,825 | 51,003 | 52,153 | 57,405 |
| Net Cash Flow | $-10,340 | $-4,328 | $-1,150 | $-22,657 | $-17,405 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,579 | -4,315 | -1,141 | -22,686 | -16,991 |
| Free Cash Flow | -8,579 | -4,315 | -1,141 | -22,686 | -16,991 |